EAST BRUNSWICK, N.J., Feb. 16, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that it is strengthening its management team with three new executive appointments as it begins the commercial launch of KRYSTEXXA™. Louis Ferrari will join Savient as Senior Vice President, North America Commercial; Christine Mikail will join Savient as Senior Vice President, Corporate Development; and Stephen Davies will join Savient as Chief Information Officer and Group Vice President. In these newly created positions, Messrs. Ferrari and Davies and Ms. Mikail will report to John H. Johnson, Chief Executive Officer.
"We are pleased to welcome Louis, Christine and Stephen to Savient," said Mr. Johnson. "This is an exciting time for Savient and these are three key additions that will help make for a successful commercial launch of KRYSTEXXA. Today's appointments will augment our already strong team of talented executives and employees, all of whom are committed to bringing this life-changing therapy to adult patients suffering from chronic gout refractory to conventional therapy. I look forward to working closely with Louis, Christine and Stephen and the entire Savient team as we embark on this next phase in Savient's history."
Mr. Ferrari comes to Savient with over 30 years of experience in the pharmaceutical industry, including expertise in product launches, new product development, international marketing, sales management, sales training, and clinical trials. At Savient, Mr. Ferrari will be responsible for all commercial activities in North America. Mr. Ferrari previously served as Vice President of Oncology and Nephrology, Sales and Marketing at Centocor Ortho Biotech, where he was responsible for sales of Procrit and Doxil. Prior to that he served as Vice President of Clinical Affairs and Executi
|SOURCE Savient Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved